What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.
Where this comes from
- Record sourced from PubMed, PMID 21387368.
- Also identified by DOI 10.1002/ana.22365.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The aborted trial of semagacestat has led some to invoke unanticipated effects of γ-secretase inhibition on formation of amyloid β. However, the many substrates for γ-secretases and the varied biological effects of each of the resultant cleavage products make ascribing causality much more complex than that.
Medical subject headings
- Alanine
- Alzheimer Disease
- Amyloid Precursor Protein Secretases
- Azepines
- Early Termination of Clinical Trials